Abstracts tagged "metabolomics"

Abstract Number: 002 • 2023 Pediatric Rheumatology Symposium
Re-analysis of the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression
Coziana Ciurtin¹, Junjie Peng¹, Pierre Donnes¹, Stacy Ardoin², Laura Schanberg³, Laura Lewandowski⁴, George A Robinson¹ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²Nationwide Children's Hospital, Columbus, OH, ³Duke University Medical Center, Durham, NC, ⁴NIAMS, NIH, Bethesda, MD
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is associated with chronic inflammation and increased risk of atherosclerosis. The APPLE trial was a randomised, placebo-controlled trial of…
Abstract Number: 1820 • ACR Convergence 2022
Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls
Blanka Stiburkova¹, Kateřina Pavelcová¹, Jana Bohatá¹, Karel Pavelka², Lenka Hasíková¹, Jakub Závada¹, Aleš Kvasnička³, Dana Dobešová³ and David Friedecký³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ³Palacky University Olomouc, Olomouc, Czech Republic
Background/Purpose: Gout is the most common type of inflammatory arthritis, characterised by chronic deposition of uric acid crystals in the joints, affecting approx. 1-2% of…
Abstract Number: 1895 • ACR Convergence 2022
Association Between Synovial Tissue Metabolomic Profile and Pain in Patients with Knee Osteoarthritis
Jessica Murillo Saich¹, Roxana Coras², Robert Meyer³, Nancy Lane⁴ and Monica Guma⁵, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego, San Diego, CA, ³San Diego VA Healthcare Service, San Diego, CA, ⁴University of California Davis, Hillsborough, CA, ⁵UCSD, La Jolla, CA
Background/Purpose: Increasing evidence indicates that osteoarthritis (OA) progression is mediated by low-grade synovial inflammation (synovitis) that contributes to joint pain and stiffness, especially in knee…
Abstract Number: 1906 • ACR Convergence 2022
Bile Acid Profile Is Associated to Synovitis in Knee Osteoarthritis
Roxana Coras¹, Jessica Murillo Saich², Michal Hose Sanchez³, Anne Quan³, Emily Gentry¹, Pieter Dorrestein¹, Nancy Lane⁴ and Monica Guma⁵, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³VA San Diego Healthcare System, San Diego, CA, ⁴University of California Davis, Hillsborough, CA, ⁵Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Increasing evidence indicates that low grade systemic and local inflammation contributes to osteoarthritis (OA) progression. Bioactive lipid mediators are signaling molecules involved in inflammatory…
Abstract Number: 1993 • ACR Convergence 2022
Changes in Omega-6- and Omega-3-Derived Bioactive Lipids in Response to an Anti-Inflammatory Dietary Intervention
Esha Lal¹, Marta Sala Climent², francesca cedola², Marta Fernandez-Bustamante³, Meritxell Agustín-Perez², Maram Alharti², Abha Singh⁴, Soo-In Choi², Tania Rivera², Katherine Nguyen⁴, Susan Lee², Aaron Armando⁵, Tiffany Holt⁶, Oswald Quehenberger⁵, Shahrokh Golshan⁶, Roxana Coras⁷ and Monica Guma⁸, ¹Department of Medicine, School of Medicine, University of California, San Diego, San Diego, ²Department of Medicine, School of Medicine, University of California, San Diego, San Diego, CA, ³Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, ⁴University of California, San Diego, San Diego, CA, ⁵Department of Pharmacology, School of Medicine, University of California, San Diego, San Diego, CA, ⁶Department of Psychiatry, School of Medicine, University of California, San Diego, San Diego, CA, ⁷University of California San Diego, San Diego, CA, ⁸UCSD, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes joint pain, swelling, stiffness, and decreased mobility. Despite the various treatment options for RA, many…
Abstract Number: 0036 • ACR Convergence 2022
Patient-specific and Disease-related Determinants for Cardiovascular Disease (CVD) Risk Stratification in the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Clinical Trial Cohort
Junjie Peng¹, George Robinson¹, Stacy P Ardoin², Laura Schanberg³, Elizabeth Jury¹ and Coziana Ciurtin⁴, ¹University College London, London, United Kingdom, ²Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ³Duke University Medical Center, Durham, NC, ⁴Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: The risk of developing cardiovascular disease (CVD) through atherosclerosis in juvenile-onset systemic lupus erythematosus (JSLE) patients is significantly increased. This study aimed to stratify…
Abstract Number: 2211 • ACR Convergence 2022
Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis
Amar Kumar¹, Joshua Tartarian², Valentina Shakhnovich³, Carl Langefeld⁴, Daniel Lovell⁵, Susan Thompson⁶, Mara Becker⁷ and Ryan Funk⁸, ¹University of Kansas, Kansas City, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Missouri-Kansas City School of Medicine & Children’s Mercy Kansas City, Kansas City, MO, ⁴Wake Forest School of Medicine, Winston Salem, NC, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Blue Ash, OH, ⁷Duke University Medical Center/Duke Clinical Research Institute, Durham, NC, ⁸University of Kansas, Leawood, KS
Background/Purpose: Identification of disease and therapeutic biomarkers remains a barrier to the early diagnosis of and initiation of effective therapy for juvenile idiopathic arthritis (JIA).…
Abstract Number: 0320 • ACR Convergence 2022
Metabolomics in Systemic Lupus Erythematosus and Pregnancy – A Prospective Observational Longitudinal Study
Shi-Nan Luong¹, Isabella Sheldon², Charles Raine³, Elizabeth Jury³ and Ian Giles³, ¹University College London, United Kingdom and University of New South Wales, Sydney, Australia, ²London School of Hygiene and Tropical Medicine, London, United Kingdom, ³University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by activation of immunological and cellular pathways, disease flares and adverse pregnancy outcomes (APO). Metabolomic…
Abstract Number: 2242 • ACR Convergence 2022
Metabolomics-based Identification of Metabolic Dysfunction in Inclusion Body Myositis
Jemima Albayda¹, Cissy Zhang¹, Pratik Khare¹, Brittany Adler¹, Erika Darrah¹, Lisa Christopher-Stine¹, Thomas E Lloyd² and Anne Le¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sporadic Inclusion Body Myositis (IBM) is the most common myopathy over the age of 50 and is currently refractory to treatment. The pathogenesis of…
Abstract Number: 0560 • ACR Convergence 2022
IL-17 Regulates Apolipoprotein E in Lymph Node Stromal Cells During Infection and Autoimmunity
Catherine Poholek¹ and Mandy McGeachy², ¹UPM Children's Hospital of Pittsburgh/University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Autoimmune disease (AID) resulting from a dysregulated immune response is associated with substantial morbidity and mortality, largely driven by cardiovascular disease (CVD)/atherosclerosis and dyslipidemia.…
Abstract Number: 0592 • ACR Convergence 2022
Autoantibodies Targeting Malondialdehyde-modifications Are Potential Mediators of Inflammation and Bone Loss in RA, Acting via Macrophage and Osteoclast Regulatory Pathways
Jitong Sun¹, Koji Sakuraba², Akilan Krishnamurthy³, Xiaowei Zheng³, Marcelo Gomes Afonso³, Cheng Xu³, Bing Peng³, Per-Johan Jakobsson³, Marianne Engström³, Fredrik Wermeling³, Sergiu Catrina³, Caroline Grönwall³, Anca Catrina³ and Bence Réthi³, ¹Karolinska Institutet, Solna, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Fukuoka, Japan, ³Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Proteins subjected to post-translational modifications, such as citrullination, carbamylation, acetylation, malondialdehyde (MDA) or malondialdehyde/acetaldehyde (MDA/MAA) modification are targeted by autoantibodies in seropositive rheumatoid arthritis…
Abstract Number: 0649 • ACR Convergence 2022
Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity
Marc Scherlinger¹, Wenliang Pan², Ryo Hisada¹, Milena Vukelic³, Masataka Umeda¹, Afroditi Boulougoura², Maria Tsokos¹ and George Tsokos², ¹BIDMC Harvard University, Boston, MA, ²Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Albert Einstein College of Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a defective T regulatory (Treg) cell compartment which participate in immune dysregulation. Although the underlying mechanism are…
Abstract Number: 0660 • ACR Convergence 2022
Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study
Audrey Hagiwara¹, Moumita Bose¹, Aleksandr Stotland¹, Aleksandra Binek¹, Koen Raedschelders¹, Janet Wei¹, C. Noel Bairey Merz¹, Sarah Parker¹, Jennifer Van Eyk¹, Daniel Wallace¹, Mariko Ishimori² and Caroline Jefferies¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Health System, Los Angeles, CA
Background/Purpose: Cardiovascular disease (CVD) is a significant cause of mortality in patients with SLE. While obstructive coronary artery disease (CAD) is a leading cause of…
Abstract Number: 0690 • ACR Convergence 2022
The Physiological Ketone Body Beta-Hydroxybutyrate Potently Neutralizes APS-Associated NETosis
Ajay Tambralli¹, Alyssa Harbaugh¹, Christine Rysenga¹, Kaitlyn Sabb¹, Srilakshmi Yalavarthi¹, Claire Hoy¹, Yu (Ray) Zuo¹ and Jason S Knight², ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: Malleable metabolic pathways guide both productive and pathological neutrophil functions, including neutrophil extracellular trap release (NETosis). NETosis plays an important role in APS pathophysiology.…
Abstract Number: 1157 • ACR Convergence 2022
Bacterial Indole Associated with Spondyloarthritis-Related Dysbiosis Contributes to Enhanced Th17 Immunity
Brenda Seymour¹, Brandon Trent², Brendan Allen³, Adam Berlinberg¹ and Kristi Kuhn³, ¹University of Colorado Anschutz Medical Campus, Denver, CO, ²University of Colorado Anschutz Medical Campus, Eugene, OR, ³University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: While intestinal dysbiosis and the Th17 pathway are linked to the pathophysiology of spondyloarthritis (SpA), the mechanisms by which this occurs are unknown. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.